CAPRIE
(1996)Objective
Clopidogrel versus aspirin for secondary prevention of ischemic events in patients with recent stroke, MI, or PAD.
Study Summary
• Clopidogrel showed a modest but statistically significant reduction in composite vascular events (stroke, MI, or CV death) compared to aspirin, with similar bleeding risk.
Intervention
Clopidogrel 75 mg daily vs. aspirin 325 mg daily.
Study Design
Arms: Array
Outcome
• Primary: Stroke, MI, or CV death 5.32% vs. 5.83% per year (RR 0.91; 95% CI 0.84–0.97; p=0.043)
• Secondary: Ischemic stroke, MI, amputation, or CV death 5.56% vs. 6.01% (p=0.076)
• CV death 1.90% vs. 2.06% (p=0.29)
• Any stroke, MI, or all-cause death 6.43% vs. 6.90% (p=0.081)
• All-cause death 3.05% vs. 3.11% (p=0.71)
• Adverse events: Rash 6.0% vs. 4.6%, diarrhea 4.5% vs. 0.23%, GI bleeding 2.0% vs. 2.7%, any bleeding 9.3% vs. 9.3%, intracranial bleed 0.35% vs. 0.49%
• Secondary: Ischemic stroke, MI, amputation, or CV death 5.56% vs. 6.01% (p=0.076)
• CV death 1.90% vs. 2.06% (p=0.29)
• Any stroke, MI, or all-cause death 6.43% vs. 6.90% (p=0.081)
• All-cause death 3.05% vs. 3.11% (p=0.71)
• Adverse events: Rash 6.0% vs. 4.6%, diarrhea 4.5% vs. 0.23%, GI bleeding 2.0% vs. 2.7%, any bleeding 9.3% vs. 9.3%, intracranial bleed 0.35% vs. 0.49%